Palisade Bio (PALI) Net Income towards Common Stockholders (2010 - 2026)
Palisade Bio (PALI) reported Net Income towards Common Stockholders of -$10.7 million for Q1 2026, down 382.02% year-over-year from $3.8 million in Q1 2025, and down 7.67% on a QoQ basis from -$10.0 million in Q4 2025.
Palisade Bio (PALI) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$10.7 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders fell 382.02% year-over-year to -$10.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$26.4 million (down 100.15% YoY) and the FY2025 annual result came in at -$18.1 million, down 21.48% from the prior year.
- Net Income towards Common Stockholders declined to -$10.7 million in Q1 2026 per PALI's latest filing, from -$10.0 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at -$2.2 million in Q1 2025 and bottomed at -$10.7 million in Q1 2026.
- The 5-year median for Net Income towards Common Stockholders is -$3.5 million (2024), against an average of -$4.1 million.
- The widest annual swing landed in 2022, when Net Income towards Common Stockholders surged 92.62%; it then tumbled 382.02% in 2026.
- Tracing PALI's Net Income towards Common Stockholders over 5 years: stood at -$3.9 million in 2022, then advanced by 18.0% to -$3.2 million in 2023, then declined by 7.19% to -$3.4 million in 2024, then tumbled by 194.92% to -$10.0 million in 2025, then dropped by 7.67% to -$10.7 million in 2026.
- Per Business Quant, the three latest PALI Net Income towards Common Stockholders figures stand at -$10.7 million (Q1 2026), -$10.0 million (Q4 2025), and -$2.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -13.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 2.50 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Palisade Bio | 439.25 Mn | 309.68 Mn | - | -10.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.75 Mn |
| Dec 31, 2025 | -9.98 Mn |
| Sep 30, 2025 | -2.87 Mn |
| Jun 30, 2025 | -2.78 Mn |
| Mar 31, 2025 | -2.23 Mn |
| Dec 31, 2024 | -3.39 Mn |
| Sep 30, 2024 | -3.49 Mn |
| Jun 30, 2024 | -4.08 Mn |
| Mar 31, 2024 | -3.53 Mn |
| Dec 31, 2023 | -3.16 Mn |
| Sep 30, 2023 | -3.79 Mn |
| Jun 30, 2023 | -3.39 Mn |
| Mar 31, 2023 | -2.34 Mn |
| Dec 31, 2022 | -3.85 Mn |
| Sep 30, 2022 | -4.42 Mn |
| Jun 30, 2022 | -2.34 Mn |
| Mar 31, 2022 | -3.89 Mn |
| Dec 31, 2021 | 6.19 Mn |
| Sep 30, 2021 | 5.12 Mn |
| Jun 30, 2021 | -31.75 Mn |
| Mar 31, 2021 | -3.66 Mn |
| Dec 31, 2020 | -4.24 Mn |
| Sep 30, 2020 | -1.84 Mn |
| Jun 30, 2020 | -1.85 Mn |
| Mar 31, 2020 | -1.98 Mn |
| Dec 31, 2019 | -2.12 Mn |
| Sep 30, 2019 | -2.11 Mn |
| Jun 30, 2019 | -1.91 Mn |
| Mar 31, 2019 | -2.43 Mn |
| Dec 31, 2018 | -1.78 Mn |
| Sep 30, 2018 | -2.07 Mn |
| Jun 30, 2018 | -2.00 Mn |
| Mar 31, 2018 | -2.33 Mn |
| Dec 31, 2017 | -2.25 Mn |
| Sep 30, 2017 | -2.57 Mn |
| Jun 30, 2017 | -4.22 Mn |
| Mar 31, 2017 | -4.35 Mn |
| Dec 31, 2016 | -5.83 Mn |
| Sep 30, 2016 | -5.14 Mn |
| Jun 30, 2016 | -4.14 Mn |
| Mar 31, 2016 | -6.61 Mn |
| Dec 31, 2015 | -4.77 Mn |
| Sep 30, 2015 | -5.64 Mn |
| Jun 30, 2015 | -5.44 Mn |
| Mar 31, 2015 | -5.05 Mn |
| Dec 31, 2014 | -5.06 Mn |
| Sep 30, 2014 | -4.46 Mn |
| Jun 30, 2014 | -3.89 Mn |
| Mar 31, 2014 | -5.58 Mn |
| Dec 31, 2013 | -3.20 Mn |
| Sep 30, 2013 | -4.06 Mn |
| Jun 30, 2013 | -3.66 Mn |
| Mar 31, 2013 | -2.93 Mn |
| Dec 31, 2012 | -2.72 Mn |
| Sep 30, 2012 | -2.58 Mn |
| Jun 30, 2012 | -2.38 Mn |
| Mar 31, 2012 | -2.46 Mn |
| Dec 31, 2011 | -2.56 Mn |
| Sep 30, 2011 | -3.21 Mn |
| Jun 30, 2011 | -3.65 Mn |
| Mar 31, 2011 | -3.51 Mn |
| Dec 31, 2010 | -1.52 Mn |
| Sep 30, 2010 | -3.91 Mn |
| Jun 30, 2010 | -4.19 Mn |